周四,诺瓦瓦克斯医药(NVAX.US)股价走高,截至发稿,该股涨超4.5%,报7.61美元。在最新公布的第四季度财报显示,公司亏损有所收窄,主要受益于新冠疫苗销售和管理费用的减少。目前,该疫苗仍是诺瓦瓦克斯医药唯一在售的产品。截至12月31日的季度,其净亏损为8100万美元,而去年同期净亏损为1.783亿美元。诺瓦瓦克斯医药第四季度新冠疫苗销售额仅为4980万美元,同比大幅下降80.2%。面对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.